The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Alzheimer's disease drug development pipeline: 2018
Open accessAbstract
Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the literature review reveals that only a single cholinesterase inhibitor is in Phase II and Phase III clinical trials, for AD management [147,148].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [148]
In the citing paper
“A number of additional pathogenic mechanisms have been described, possibly overlapping with Aβ plaques and NFT formation or induced by them, including inflammation, oxidative damage, iron deregulation, and cholesterol metabolism blood-brain barrier (BBB) dysfunction or α-synuclein toxicity.9-13”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Research works printed but not linked: 1
- Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease
Cited by
Sorted by citations
Items 301–400 of 701
Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success
Boucherie, D. M., Duarte, G. S., Machado, T. L. G. N., Faustino, P., Sampaio, C., Rascol, O., & Ferreira, J. J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202184 · Cited by 30
Song, L., Oseid, D. E., Wells, E. A., Coaston, T. N., & Robinson, A. S. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01943-2 · Cited by 28
Tackling gaps in developing life‐changing treatments for dementia
Mauricio, R., Benn, C., Davis, J. B., Dawson, G. R., Dawson, L. A., Evans, A., Fox, N. C., Gallacher, J., Hutton, M., Isaac, J. T. R., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.001 · Cited by 27
An Overview of Glutaminyl Cyclase Inhibitors for Alzheimer’s Disease
Coimbra, J. R. M., Sobral, P. J. M., Santos, A. E., Moreira, P. I., & Salvador, J. A. R. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0163 · Cited by 25
Amyloid Oligomers, Protofibrils and Fibrils
Siddiqi, M. K., Majid, N., Malik, S., Alam, P., & Khan, R. H. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-28151-9_16 · Cited by 25
COVID-19 and the brain: impact on nuclear medicine in neurology
Morbelli, S. D., Ekmekçioğlu, Ö., Barthel, H., Albert, N. L., Boellaard, R., Cecchin, D., Guedj, É., Lammertsma, A. A., Law, I. G., Peñuelas, I., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04965-x · Cited by 25
Wang, Y., Gong, W.-G., Ren, Q., & Zhang, Z. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200401 · Cited by 26
Mitra, S., Gera, R., Linderoth, B., Lind, G., Wahlberg, L. U., Almqvist, P. M., Behbahani, H., & Eriksdotter, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_11 · Cited by 27
Clinical Text Classification of Alzheimer’s Drugs’ Mechanism of Action
Kambar, M. E. Z. N., Nahed, P., Cacho, J. R. F., Lee, G., Cummings, J. L., & Taghva, K. (2021) · Lecture notes in networks and systems · doi:10.1007/978-981-16-2377-6_48 · Cited by 25
Self-citationLi, F., Eteleeb, A. M., Buchser, W., Sohn, C., Wang, G., Xiong, C., Payne, P., McDade, E., Karch, C. M. M., Harari, O., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.935279 · Cited by 27
Namsi, A., Nury, T., Khan, A. S., Leprince, J., Vaudry, D., Caccia, C., Leoni, V., Atanasov, A. G., Tonon, M., Masmoudi‐Kouki, O., et al. (2019) · Molecules · doi:10.3390/molecules24183310 · Cited by 25
Carrera, I., Martínez, O., & Cacabelos, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191202155738 · Cited by 25
Ríos, X., Gómez‐Vallejo, V., Martín, A., Cossío, U., Morcillo, M. Á., Alemi, M., Cardoso, I., Quintana, J. R., Jiménez‐Barbero, J., Cotrina, E. Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50071-w · Cited by 24
Lam, J., Hlávka, J. P., & Mattke, S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.06.180328 · Cited by 24
Ikenoue, T., Aprile, F. A., Sormanni, P., Ruggeri, F. S., Perni, M., Heller, G. T., Haas, C. P., Middel, C., Limbocker, R., Mannini, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69626-3 · Cited by 24
Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration
Miatmoko, A., Hariawan, B. S., Cahyani, D. M., Dewangga, S. S., Handoko, K. K., Purwati, P., Sahu, R. K., & Hariyadi, D. M. (2023) · Journal of Biological Engineering · doi:10.1186/s13036-023-00331-1 · Cited by 24
Llorach-Parés, L., Rodríguez-Urgellés, E., Nonell‐Canals, A., Alberch, J., Àvila, C., Sánchez-Martínez, M., & Giralt, A. (2020) · Biomolecules · doi:10.3390/biom10040639 · Cited by 24
Ashrafizadeh, M., Zarrabi, A., Najafi, M., Samarghandian, S., Mohammadinejad, R., & Ahn, K. S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6732 · Cited by 24
Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Sharma, V., Singh, T. G., & Singh, S. (2020) · Current Drug Targets · doi:10.2174/1389450121666200727104728 · Cited by 23
Kundu, D., & Dubey, V. K. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721999201208200605 · Cited by 23
Živančević, K., Baralić, K., Božić, D., Miljaković, E. A., Djordjević, A. B., Ćurčić, M., Bulat, Z., Antonijević, B., Bulat, P., & Đukić-Ćosić, D. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.112839 · Cited by 23
Therapeutic anti‐amyloid β antibodies cause neuronal disturbances
Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 24
Current viral-mediated gene transfer research for treatment of Alzheimer’s disease
Sasmita, A. O. (2018) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2018.1523521 · Cited by 26
Are large simple trials for dementia prevention possible?
Whiteley, W. N., Anand, S. S., Bangdiwala, S. I., Bosch, J., Canavan, M. D., Chertkow, H. M., Gerstein, H. C., Gorelick, P. B., O'Donnell, M. J., Paré, G., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz152 · Cited by 24
Sanchís, I., Spinelli, R., Aschemacher, N. A., Húmpola, M. V., & Siano, Á. (2020) · Amino Acids · doi:10.1007/s00726-019-02815-1 · Cited by 22
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 23
Purgatorio, R., Boccarelli, A., Pisani, L., de Candia, M., Catto, M., & Altomare, C. (2024) · Antioxidants · doi:10.3390/antiox13010133 · Cited by 21
Uspenskaya, O., Alamuri, C., Wang, L., Yang, M., Khinda, S., Nigmatullina, Y., Cao, T., Kayal, N., O’Keefe, M., & Rubel, C. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.10 · Cited by 23
Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease?
Willbold, D., & Kutzsche, J. (2019) · Molecules · doi:10.3390/molecules24122237 · Cited by 21
Delivoria, D. C., Chia, S., Habchi, J., Perni, M., Matis, I., Papaevgeniou, N., Reczko, M., Chondrogianni, N., Dobson, C. M., Vendruscolo, M., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax5108 · Cited by 22
Westwood, S., Baird, A. L., Anand, S. N., Nevado‐Holgado, A. J., Kormilitzin, A., Shi, L., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190434 · Cited by 25
Ugbaja, S. C., Lawal, I. A., Kumalo, H. M., & Lawal, M. M. (2021) · Current Drug Targets · doi:10.2174/1389450122666210809100050 · Cited by 22
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
Kern, D. M., Cepeda, M. S., Lovestone, S., & Seabrook, G. R. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.07.012 · Cited by 21
Žiaunys, M., Mikalauskaitė, K., & Smirnovas, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-56788-y · Cited by 21
Cummings, J. L. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20060152 · Cited by 21
Self-citationGodyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21
Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease
Paliwal, D., McInerney, T. W., Pa, J., Swerdlow, R. H., Easteal, S., Andrews, S. J., & Initiative, F. T. A. D. N. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.005 · Cited by 21
A Report From the 8th Kuopio Alzheimer Symposium
Haapasalo, A., & Hiltunen, M. (2018) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0029 · Cited by 22
Thientunyakit, T., Sethanandha, C., Muangpaisan, W., Chawalparit, O., Arunrungvichian, K., Siriprapa, T., Vichianin, Y., Kamal, S., Suppasilp, C., Thongpraparn, T., et al. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01453-y · Cited by 21
Zhao, H., Huang, X., & Tong, Z. (2021) · ChemMedChem · doi:10.1002/cmdc.202100428 · Cited by 21
Arastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
Fucoidans inhibited tau interaction and cellular uptake
Jin, W., Lu, C., Zhu, Y., Zhao, J., Zhang, W., Wang, L., Linhardt, R. J., Wang, C., & Zhang, F. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.120176 · Cited by 19
Alachkar, A., Khan, N., Łażewska, D., Kieć‐Kononowicz, K., & Sadek, B. S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s193125 · Cited by 21
Hematologic safety of chronic brain‐penetrating erythropoietin dosing in APP/PS1 mice
Sun, J., Yang, J., Whitman, K., Zhu, C., Cribbs, D. H., Boado, R. J., Pardridge, W. M., & Sumbria, R. K. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.003 · Cited by 19
Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data
Nader, C. A., Ayache, N., Frisoni, G. B., Robert, P. H., Lorenzi, M., & Initiative, A. D. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab091 · Cited by 22
Păunescu, H., Dima, L., Ghiţă, I., Coman, L., Ifteni, P. I., Fulga, I., & Coman, O. A. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001120 · Cited by 19
Monteiro‐Fernandes, D., Silva, J. M., Soares‐Cunha, C., Dalla, C., Kokras, N., Arnaud, F., Billiras, R., Zhuravleva, V., Waites, C. L., Bretin, S., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0794-5 · Cited by 20
Kanchi, P. K., & Dasmahapatra, A. K. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04968-x · Cited by 19
Penny, L. K., Lofthouse, R. A., Arastoo, M., Porter, A., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00417-w · Cited by 20
Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity
Takechi, H., Kokuryu, A., Kuzuya, A., & Matsunaga, S. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13764 · Cited by 19
Wu, P.-C., Fann, M., Tran, T. T., Chen, S.-C., Devina, T., Cheng, I. H.-J., Lien, C., Kao, L., Wang, S., Fuh, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55614-9 · Cited by 17
Li, Y., Wang, Y., Wang, J., Chong, K. Y., Xu, J., Liu, Z., & Shan, C. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.012 · Cited by 19
Chung, Y.-S., Choo, B. K. M., Ahmed, P. K., Othman, I., & Shaikh, M. F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00692 · Cited by 21
Imbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 20
Novel Pharmaceutical Approaches in Dementia
Tanaka, M., Török, N., & Vécsei, L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_444-1 · Cited by 20
San-Martin, R., Johns, E. K., Mamani, G. Q., Tavares, G., Phillips, N. A., & Fraga, F. J. (2021) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2021.102499 · Cited by 19
From reaction kinetics to dementia: A simple dimer model of Alzheimer’s disease etiology
Lindstrom, M. R., Chavez, M. B., Gross-Sable, E. A., Hayden, E. Y., & Teplow, D. B. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009114 · Cited by 19
Evaluating Cannabis sativa L.’s neuroprotection potential: From bench to bedside
Laws, J. S., & Smid, S. D. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154485 · Cited by 18
The β‐adrenergic hypothesis of synaptic and microglial impairment in Alzheimer's disease
Li, S. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15782 · Cited by 18
Probiotics that Ameliorate Cognitive Impairment through Anti-Inflammation and Anti-Oxidation in Mice
Lee, S., Eom, S., Lee, J., Pyeon, M., Kim, K., Choi, K. Y., Lee, J., Shin, D. J., Lee, K. H., Oh, S., et al. (2023) · Food Science of Animal Resources · doi:10.5851/kosfa.2023.e22 · Cited by 18
Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
Cuello, A. C., Hall, H., & Carmo, S. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00189 · Cited by 21
Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?
Hadar, A., & Gurwitz, D. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.4/dgurwitz · Cited by 18
Interaction of selected biomolecules and metabolites with amyloidogenic proteins
Kundu, D., Umesh, & Dubey, V. K. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1760138 · Cited by 18
Masuda, Y., Fujihara, K., Hayashi, S., Sasaki, H., Kino, Y., Kamauchi, H., Noji, M., Satoh, J., Takanami, T., Kinoshita, K., et al. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c01329 · Cited by 19
Optimal two-stage designs based on restricted mean survival time for a single-arm study
Shan, G. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100732 · Cited by 18
Methylene Blue Blocks and Reverses the Inhibitory Effect of Tau on PMCA Function
Berrocal, M., Caballero-Bermejo, M., Gutierrez-Merino, C., & Mata, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143521 · Cited by 17
Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Law, C. S. W., & Yeong, K. Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312114223 · Cited by 17
Deng, Y., Li, W., Niu, L., Luo, X., Li, J., Zhang, Y. E., Liu, H., He, J., & Wan, W. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136209 · Cited by 17
Li, Y., Nguyen, M., Baudoin, M., Vendier, L., Liu, Y., Robert, A., & Meunier, B. (2019) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201900951 · Cited by 16
Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease
Wilkins, J. M., & Forester, B. P. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5262 · Cited by 17
Vasilopoulou, F., Bagán, A., Rodríguez‐Arévalo, S., Escolano, C., Griñán‐Ferré, C., & Pallàs, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050475 · Cited by 17
Vasilopoulou, F., Griñán‐Ferré, C., Rodríguez‐Arévalo, S., Bagán, A., Abás, S., Escolano, C., & Pallàs, M. (2020) · GeroScience · doi:10.1007/s11357-020-00281-2 · Cited by 19
Nguyen, T. T., Vo, T. K., & Vo, G. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_13 · Cited by 18
Essential Oils in Experimental Models of Neuropsychiatric Disorders: A Systematic Review
Fernandes, L. C. B., da Costa, I. M., Freire, M. A. M., Lima, F. O. V., Neta, F. I., Lucena, E. E. D. S., Alves, R. D., Cavalcanti, J. R. L. D. P., Pinheiro, F. I., de Azevedo, E. P., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210421091734 · Cited by 17
Mạnh, N. V., Hoang, V.-H., Ngo, V. T. H., Ann, J., Jang, T., Ha, J.-H., Song, J. Y., Ha, H.-J., Kim, H., Kim, Y.-H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113819 · Cited by 17
Zhang, N., Zheng, X., Liu, H., Zheng, Q., & Li, L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00630-5 · Cited by 16
Su, I., Hsu, C., Shen, S.-T., Chao, P., Hsu, J. T., Hsueh, J., Liang, J., Hsu, Y.-T., & Shie, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010556 · Cited by 17
Sa, P., Singh, P., Dilnawaz, F., & Sahoo, S. K. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220729104433 · Cited by 16
Human stem cell transplantation models of Alzheimer’s disease
Ifediora, N., Canoll, P., & Hargus, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1354164 · Cited by 18
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
Ion, D., Mihai, D. P., Lupașcu, G., & Nițulescu, G. M. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1526115 · Cited by 16
Carbon Nanostructure-Based Materials: A Novel Tool for Detection of Alzheimer’s Disease
Ashfaq, M., Talreja, N., Chuahan, D., & Srituravanich, W. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_4 · Cited by 16
A unified model of dementias and age‐related neurodegeneration
Fossel, M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12012 · Cited by 16
Amyloid beta peptide-degrading microbial enzymes and its implication in drug design
Dhanavade, M. J., & Sonawane, K. D. (2020) · 3 Biotech · doi:10.1007/s13205-020-02240-2 · Cited by 16
Banks, S. J., Qiu, Y., Fan, C. C., Dale, A. M., Zou, J., Askew, B., Feldman, H., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12071 · Cited by 15
da Silva, W. M. B., Pinheiro, S. D. O., Alves, D. R., de Menezes, J. E. S. A., Magalhães, F. E. A., Silva, F. C. O., Marinho, M. M., Marinho, E. S., & de Morais, S. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00306-w · Cited by 16
The Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 16
Modeling the Effects of Yoga on the Progression of Alzheimer’s Disease in a Dish
Hassan, A., Robinson, M., & Willerth, S. M. (2018) · Cells Tissues Organs · doi:10.1159/000499503 · Cited by 17
Teo, E., Fong, S., Tolwinski, N. S., & Gruber, J. (2020) · GeroScience · doi:10.1007/s11357-020-00169-1 · Cited by 18
Singh, R. K. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04369-7 · Cited by 16
Johnson, R. A. (1974) · PubMed Central · Cited by 16
The Therapeutic Potential of Epigenetic Modifications in Alzheimer’s Disease
Bufill, E., Nogué, R. R., & Blesa, R. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch9 · Cited by 15
Experimental modelling of Alzheimer's disease for therapeutic screening
Blaikie, L., Kay, G., Maciel, P., & Lin, P. K. T. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100044 · Cited by 16
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 17
Rethinking monogenic neurological diseases
Chen, W., Cheng, X., Fu, Y., Zhao, M., McGinley, J. L., Westenberger, A., & Xiong, Z. (2020) · BMJ · doi:10.1136/bmj.m3752 · Cited by 16
Sun, P., Hu, Y., Xing, Q., Deng, W., Ou, Y., Pan, G., Zhong, X., & Hu, W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00073 · Cited by 15
Philbert, S. A., Xu, J., Unwin, R. D., Dowsey, A. W., & Cooper, G. J. S. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.107 · Cited by 15
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 16
Metadata
- Authors
- Cummings, J., Lee, G., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 195-214
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021548
- OpenAlex
- W2918066696
- Cited by
- 697
- References
- 48
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
- FWCI
- 91.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
